Recent Research Analysts’ Ratings Changes for Bio-Techne (TECH)

Several analysts have recently updated their ratings and price targets for Bio-Techne (NASDAQ: TECH):

• 2/19/2025 – Bio-Techne was downgraded by analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating. They now have a $68.00 price target on the stock, down previously from $88.00.
• 2/6/2025 – Bio-Techne had its price target raised by analysts at Royal Bank of Canada from $79.00 to $80.00. They now have a “sector perform” rating on the stock.
• 2/6/2025 – Bio-Techne had its price target raised by analysts at Scotiabank from $88.00 to $90.00. They now have a “sector outperform” rating on the stock.
• 2/6/2025 – Bio-Techne had its price target raised by analysts at KeyCorp from $80.00 to $90.00. They now have an “overweight” rating on the stock.

Bio-Techne Price Performance

TECH stock traded up $0.41 during trading on Wednesday, reaching $65.70. The company’s stock had a trading volume of 1,031,284 shares, compared to its average volume of 1,282,738. The company has a quick ratio of 2.77, a current ratio of 3.94 and a debt-to-equity ratio of 0.14. The company’s fifty day moving average is $73.59 and its 200-day moving average is $73.73. The company has a market capitalization of $10.39 billion, a P/E ratio of 66.36, a price-to-earnings-growth ratio of 2.90 and a beta of 1.27. Bio-Techne Co. has a 1 year low of $61.16 and a 1 year high of $85.57.

Bio-Techne (NASDAQ:TECH) last issued its earnings results on Wednesday, February 5th. The biotechnology company reported $0.35 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by ($0.03). Bio-Techne had a net margin of 13.22% and a return on equity of 12.73%. On average, research analysts expect that Bio-Techne Co. will post 1.67 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, February 28th. Stockholders of record on Monday, February 17th will be issued a $0.08 dividend. This represents a $0.32 annualized dividend and a dividend yield of 0.49%. The ex-dividend date of this dividend is Friday, February 14th. Bio-Techne’s dividend payout ratio (DPR) is presently 32.32%.

Insider Buying and Selling

In other Bio-Techne news, CEO Kim Kelderman sold 13,392 shares of the firm’s stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $77.29, for a total transaction of $1,035,067.68. Following the completion of the transaction, the chief executive officer now owns 39,004 shares in the company, valued at $3,014,619.16. This trade represents a 25.56 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Amy E. Herr sold 1,860 shares of Bio-Techne stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $65.96, for a total value of $122,685.60. Following the completion of the sale, the director now directly owns 1,976 shares in the company, valued at approximately $130,336.96. The trade was a 48.49 % decrease in their position. The disclosure for this sale can be found here. 3.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. lifted its position in Bio-Techne by 46.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,650 shares of the biotechnology company’s stock valued at $1,215,000 after purchasing an additional 5,295 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Bio-Techne by 58.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 43,298 shares of the biotechnology company’s stock valued at $3,119,000 after buying an additional 16,038 shares during the period. Oddo BHF Asset Management Sas purchased a new stake in shares of Bio-Techne in the third quarter valued at $1,188,000. Quest Partners LLC bought a new stake in shares of Bio-Techne in the 3rd quarter worth about $43,000. Finally, Broadcrest Asset Management LLC boosted its stake in shares of Bio-Techne by 100.0% during the 3rd quarter. Broadcrest Asset Management LLC now owns 200,000 shares of the biotechnology company’s stock worth $15,986,000 after purchasing an additional 100,000 shares during the period. 98.95% of the stock is owned by hedge funds and other institutional investors.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.